Medical equipment company Vector Science & Therapeutics Corp (TSXV:PAIN) announced on Wednesday the expansion of its intellectual property portfolio to 15 patent applications developed and filed over approximately the past two years.

Vector's expanding IP estate is focused on delivering therapeutic agents -- including peptides and other biologics that are frequently difficult to administer outside the gastrointestinal tract -- to the right tissue, at the right concentration, for the appropriate duration of treatment.

Rather than focusing on a single drug, device or disease indication, Vector's intellectual property strategy has been built around a portfolio of interconnected therapeutic delivery technologies. Its patent applications encompass non-invasive, minimally invasive and locoregional systems intended to overcome biological, anatomical and patient-compliance barriers that can limit conventional pharmaceutical administration.